Equities research analysts at Deutsche Bank increased their price target on shares of GlaxoSmithKline (LON: GSK) from $21.51 (1440 GBX) to $22.85 (1530 GBX) in a research note issued to investors on Monday. The firm currently has a “hold” rating on the stock.

A number of other analysts have also recently weighed in on GSK. Analysts at Panmure Gordon reiterated a “buy” rating on shares of GlaxoSmithKline in a research note to investors on Wednesday, March 6th. They now have a $22.93 price target on the stock. Separately, analysts at Bryan Garnier & Cie reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note to investors on Tuesday, March 5th. They now have a $23.75 price target on the stock. Finally, analysts at JP Morgan Cazenove reiterated an “underweight” rating on shares of GlaxoSmithKline in a research note to investors on Tuesday, March 5th. They now have a $21.95 price target on the stock.

Shares of GlaxoSmithKline opened at 1486.00 on Monday. GlaxoSmithKline has a one year low of GBX 1314.00 and a one year high of GBX 1556.50. The stock’s 50-day moving average is currently GBX 1437.31. The company’s market cap is £71.729 billion.

GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.